Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases
NCT ID: NCT06029335
Last Updated: 2023-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2020-09-01
2023-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: General clinical data, some serum biomarkers including CCl-18, YKL-40, COMP, VEGF, Galectin-3, and Pentraxin as well as results of functional, quality of life, and neuropsychological measures, the Mini-Mental State Examination (MMSE), the Digit Span Forward-Backward, the Trail making A, B and the Digit Symbol tests all were administered.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT00042523
fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus
NCT06226324
Occupational and Environmental Causes of Autoimmune Diseases
NCT07000903
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:
NCT02890121
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control
NCT02890147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diffuse cutaneous Systemic sclerosis
Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
No interventions assigned to this group
Limited cutaneous Systemic sclerosis
Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
No interventions assigned to this group
Primary Raynaud's
Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
No interventions assigned to this group
Healthy
Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
No interventions assigned to this group
Rheumatoid arthritis
Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
No interventions assigned to this group
Inflammatory myopathies
Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
No interventions assigned to this group
Systemic lupus erythematosus
Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy individuals - as controls
Exclusion Criteria
* Presence of pregnancy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pecs
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
dr Varjú Cecília
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pécs, Department of Rheumatology and Immunology
Pécs, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Olah C, Schwartz N, Denton C, Kardos Z, Putterman C, Szekanecz Z. Cognitive dysfunction in autoimmune rheumatic diseases. Arthritis Res Ther. 2020 Apr 15;22(1):78. doi: 10.1186/s13075-020-02180-5.
Krampek L, Kiss F, Farkas N, Faludi R, Nagy G, Szabo A, Czirjak L, Varju C. Risk factors of cognitive function impairment in patients with systemic sclerosis. Clin Exp Rheumatol. 2025 Aug;43(8):1481-1491. doi: 10.55563/clinexprheumatol/isx6h8. Epub 2025 Aug 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05570-6/2023
Identifier Type: OTHER
Identifier Source: secondary_id
35147-3/2020/ EÜIG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.